8-KMaterial AgreementsOther EventsExhibits & Filings

DEXCOM INC 8-K Report, Material Agreement (Jan 30, 2009)

Filed January 30, 2009For Securities:DXCM

Summary

DexCom, Inc. (DXCM) filed an 8-K on January 30, 2009, to report the entry into a material definitive agreement for a public offering of its common stock. The company entered into a Purchase Agreement with Piper Jaffray & Co. as the underwriter to sell an aggregate of 15,994,000 shares of common stock. The offering is structured with 15,844,000 shares being offered to the public at $3.00 per share, and an additional 150,000 shares to be purchased by the CEO, Terrance H. Gregg, at $3.12 per share, reflecting the last reported bid price. This offering is being conducted under an existing shelf registration statement filed with the SEC. The proceeds from this offering will provide DexCom with additional capital. The transaction is expected to close on February 4, 2009. The filing also includes supporting legal opinions and consents related to the share offering.

Key Highlights

  • 1DexCom entered into a common stock purchase agreement with Piper Jaffray & Co. as underwriter.
  • 2The agreement provides for the sale of 15,994,000 shares of DexCom common stock.
  • 315,844,000 shares are offered to the public at $3.00 per share.
  • 4CEO Terrance H. Gregg will purchase 150,000 shares at $3.12 per share.
  • 5The offering is being conducted under an existing shelf registration statement.
  • 6The offering is expected to settle on February 4, 2009.
  • 7The filing includes related legal opinions and consents.

Frequently Asked Questions

This Form 8-K filing announces DexCom's entry into a material definitive agreement, specifically a common stock purchase agreement with Piper Jaffray & Co. for a public offering of its shares.

DexCom plans to sell a total of 15,994,000 shares. The majority, 15,844,000 shares, will be offered to the public at $3.00 per share, while the CEO will purchase 150,000 shares at $3.12 per share.

The offering is being made in connection with DexCom's shelf registration statement on Form S-3, including a prospectus supplement filed pursuant to Rule 424(b)(5).

The offering is expected to settle on February 4, 2009.